DocWire News Editors

DocwireNews

Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant inflammatory syndrome do not differ from patients with non-inflammatory WM in terms of response to treatment, progression-free survival (PFS), transformation to diffuse large B-cell lymphoma (DLBCL), or even overall survival (OS). This is according to a study presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition by lead study author Dikelele Elessa, MD, of the Hôpitaux de Paris in France.
The study was a retrospective analysis that included 242 patients with WM who were followed at a single hospital in France between 2007 and 2018. Dr. Elessa and colleagues identified 67 patients who had an inflammatory phenotype characterized by elevated C-reactive protein (CRP), among other factors. Another nine patients were determined to have an inflammatory syndrome of unknown origin.
At the time of treatment initiation, the median age of the study cohort was 69 years. The median CRP was 40.5mg/L, which correlated with fibrinogen (95% confidence interval [CI], 0.18-0.76; P=0.006) and inversely correlated with albuminemia (P&lt;0.001).
Inflammatory syndrome represented an indication for front-line therapy in 40% (n=20) of patients. A total of 62 patients were treated, with 60% of patients receiving rituximab-based therapy and 39% receiving monotherapy. The overall response rate was 84%. There was a significant association between inflammatory and hematological response (odds ratio, 13.8; 95% CI, 2.07-74.6; P=0.005).
Over a median follow-up of 12.6 years, the median PFS following front-line therapy was 32 months. The estimated PFS in this population was 68% (95% CI, 55-78) at 10 months, 59% (95% CI, 46-70) at 20 months, and 30% (95% CI, 19-42) at five years.
There was no difference between patients with versus without the inflammatory phenotype in terms of the median OS (14.0 vs. 16.4 years, respectively; P=0.71). At five years, the estimated OS in patients with the inflammatory phenotype was 85% (95% CI, 71-93) versus 84% (95% CI, 75-90) in patients without an inflammatory phenotype. Overall, three patients received a secondary diagnosis of DLBCL.
“Studying medullary cytokine environment, WM cells, tumoral microenvironment, and M paraprotein contributions could elucidate the underlying pathophysiological mechanisms involved,” the researchers concluded.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Inflammatory Phenotype Does Not Appear to Impact Survival, Disease Transformation in Waldenstrom Macroglobulinemia

ASH Annual Meeting 2020

Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant inflammatory syndrome do not differ from patients with ...

Inflammatory Phenotype Does Not Appear to Impact Survival, Disease Transformation in Waldenstrom

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe